Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony- stimulating factor

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 914-920

  Kemper, Carol A ^a   Bermudez, Luiz E ^b   Deresinski, Stanley C ^b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MONOCYTE; MYCOBACTERIOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031969767     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515249     Document Type: Article

References (14)

1. Kemper CA, Deresinski SC. Mycobacterium avium complex infection in AIDS. In: Volberding P, Jacobson M, eds. AIDS clinical review 1995/ 1996. New York: Marcel Dekker, 1996:153-230.
2. Havlir DV, Dube M, Sattler F, et al. A double-blind, randomized study of weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335:392-8.
3. Dube MP, Sattler FR, Torriani FR, et al. Prevention of relapse of MAC bacteremia in AIDS: a randomized study of clarithromycin plus clofazimine, with or without ethambutol [abstract 206]. 3rd Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Disease Society of America, 1996:91.
4. Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996;335:377-83.
5. Chaisson RE, Reiser P, Peirce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11:311-7.
6. Bermudez LE, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol 1990;48:67-73.
7. Bermudez LE, Martinelli J, Petrofsky M, Kolonoski P, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects on antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis 1994;169:575-80.
8. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 1991;49:380-7.
9. Havlir D, Kemper CA, Bartok A, Deresinski SC, McCutchan JA. Reproducibility of lysis-centrifugation cultures for quantification of Mycobacterium avium complex bacteremia. J Clin Microbiol 1993;31:1794-8.
10. Bermudez LM, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-γ, is associated with macrophage killing of Mycobacterium avium complex. J Immunol 1988:140:3006-13.
11. Bermudez LE, Kolonoski PT, Young LS. Natural killer cell activity and macrophage dependent inhibition of growth or killing of Mycobacterium avium complex in a mouse model. J Leukoc Biol 1990;47:135-42.
12. Meylan PR, Richman DD, Kombluth RS. Characterization and growth in human macrophages of Mycobacterium avium complex strains isolated from the blood of patients with acquired immunodeficiency syndrome. Infect Immun 1990;58:2564-8.
13. Newman GW, Kelley TG, Gan H, et al. Concurrent infection of human macrophages with HIV-1 and Mycobaclerium avium results in decreased cell viability, increased M. avium multiplication, and altered cytokine production. J Immunol 1993;151:2261-72.
14. Fournie JJ, Adams E, Mullins RJ, Basten A. Inhibition of human lympho-proliferative responses by mycobacterial phenolic glycolipids. Infect Immun 1989;57:3653-9.